Bookkeeping. I added Visa as Pick #5 for my New World of Dividend Investors Special Report (You can find it in the Special Report section of this site along with all the content on this market and its trends for Dividend Income investors. But I’m reposting it as a stand alone pick so no one misses it.
Apple is likely to take its shareholders on an even wilder ride in the next six months than they’ve been on since the December all-time high at $199.62. The end result, I think is likely to be a renewed rally beginning in the fall–if you can either hold on through the volatility until then or see your way clear to timing when to buy and sell.
First, it was Viking Therapeutics (VKTX) on the attack with trial results that shows its GLP-1 dibetes/weight loss drug out performing current leader of the pack drugs fro Novo Nordisk (NVO) and Eli Lilly (LLY). On the news Viking soared.
Then Novo Nordisk struct back with data of its own showing progress on an oral formulation of its rugs. (All existing GLP-1 drugs are delivered by injection.) That cratered Viking Shares. Now, March 26, Viking has released new Phase 1 trial data from a multiple ascending dose study of the oral version of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
Today’s Hot Button Moves NOW video is Buy Madrigal Pharmaceuticals (MDGL). This biotech company just received U.S. Food and Drug Administration approval for the first drug available for treating MASH (formerly known as NASH). MASH is a liver disease where fat builds up and compromise liver function. It’s measured in stages (1-4) and at stage 4, you need a liver transplant. Companies have long worked toward a treatment for the disease but have failed in trials or in getting FDA approval. The major achievements for Madrigal are efficacy in stopping the disease from progressing to the next stage and a clean label and no “black box warnings.” Additionally, this drug does not require a liver biopsy before a doctor can prescribe it and will be available after a much less invasive test. The market for this drug is forecast at $5 billion a year market. Madrigal will be able to start selling this drug in April. The Medical Technology Stock Letter, my preferred source on all things biotech, suggests buying MDGL below $300 with a target price of $400. I’m adding Madrigal Pharmaceuticals to my 12-18 month Jubak’s Picks Portfolio.
Let’s say you’re a dividend income investor. You need cash income in retirement. Or you want your portfolio to generate cash now so you can invest in new opportunities. Or you just want the extra safety and lower risk that owning a stock with a substantial dividend can bring. Whatever your reasons–and I can think of a lot more–this is a particularly challenging financial market for dividend income investors.But I do think there are strategies dividend income investors can successfully pursue even in this challenging market. In the rest of this Special Report I’m going to explain the three ways I think you should be thinking about dividend income investing in this market. And then I’m going to give you 10 dividend stocks that I think are especially well-suited to producing income (and price appreciation, which is always nice even if you’re an income investor) in this market environment. First pick just posted–Pfizer
Today’s Hot Button Moves NOW video is AI Woodstock. Nvidia’s big AI update on March 18 has been dubbed “AI Woodstock” by Bank of America. Nvidia will update its pipeline and prospects for new projects and report on where it sees the AI market going. It will likely create volatility throughout the AI sector as investors try to get out ahead of the company’s projections. Tuesday, Bank of America raised its target price for Nvidia from $925 to $1100 and upped its estimate of the size of the AI accelerator market from under $250 billion to $250-500 billion in 3-5 years. This wide gap in both market size and time makes me a little nervous, but for now we can focus on the next few days. Nvidia will be discussing its new B1000 and N100 chips, ethernet switches, and AI at the Edge for PCs and smartphones. Keep an eye on stocks like Broadcom (AVGO), Qualcomm (QCOM) and Super Micro Computer (SMCI) for reaction to this news. The volatility in the reaction could open up a good place to get in on these AI stocks.
Today’s Quick Pick is Qualcomm, (QCOM). I always look for product momentum in technology stocks, and Qualcomm’s pipeline is very promising. The company reported a good first quarter for 2024 but I’m focused on growth for their Snapdragon chip which is used in cell phones, cars, and the internet of things. Qualcomm has recently renewed its chip agreements with Apple and Samsung. Samsung’s Galaxy 24 is the first cell phone to include AI technology powered by Snapdragon and sales are up 13% year over year from 2023 and 47% from 2024. It’s likely more companies will be looking to add AI to their phones and I think Qualcomm has a leading position in that market. A new Snapdragon product, X-Elite, will put AI on PCs and is coming out this year. In 2023 the Snapdragon chip was also installed in infotainment modules for 75 new car models and the company’s automotive revenue is up about 12% this quarter. The Internet of Things is growing more slowly but is still growing. Morningstar says the stock is trading at a 22% premium, but I find that to be very, very conservative. While this stock isn’t a bargain at the moment this is a decent time to get in on an AI stock with promising pipeline momentum, and I don’t see it being more reasonable any time soon. I added Qualcomm to my Jubak’s Picks Portfolio on January 15, 2024. The position is up 23.5% since then as of the close on March 12.
Shares of Viking Therapeutics (VKTX) are down norther 6.22% as of noon today in New York. That comes after the stock dropped 18.84% yesterday. I think that the market thinking here by and large wrong and I’d use the big painful drop as an opportunity to buy more shares of Viking Therapeutics.
Yes, I know this is my third post (plus video) on diabetes/weight-loss drug leader Novo Nordisk (NVO) in three weeks. But the company keeps pumping out research updates that keep powering the stock higher. Think of this as a momentum stock where the momentum comes from the R&D pipeline and not moves in the share price. (The last post was https://jubakam.com/another-reason-t…-success-for-glp/) Today, the company reported early results for a next-generation oral weight loss drug called amycretin, showing a 13.1% weight loss after 12 weeks. That’s a bigger weight-loss than either Novo Nordisk’s own Wegovy or Eli Lilly’s (LLY) competing drug Zepbound. Shares of Novo Nordisk were up 8.9% today to $135.85. I added them to my Jubak’s Picks Portfolio on February 20. The position is up 11.91% since then.
Back on February 20, I posted a video recommending a buy of Novo Nordisk (NVO). In the video, “Buy GLP-1,” I said that the stock, along with Eli Lilly (LLY) was riding the momentum of increased sales of GLP-1 drugs, originally developed to treat diabetes, as weight-loss drugs. Buy, I said, despite the huge run-up in the shares, because new trials and analysis of existing data were pointing to expanded uses for the drugs. Today, Novo Nordic announced exactly the kind of news that I had talked about.
Today’s Hot Button Moves NOW video is Buy Viking Therapeutics (VKTX). Last week I suggested that you buy GLP-1 drug stocks like Eli Lilly (LLY) or Novo Nordisk (NVO). This class of diabetes and weight loss drugs is growing rapidly, with $36.5 billion in sales in 2023. Viking Therapeutics, a development-stage biotech company, recently announced Phase 2 trial results for its compound VK2735. This drug has the potential to be the best in its class when it hits the market. The company still has to go through Phase 3 trials and approval, but the data show VK2735 to be more effective at weight loss than its competitors. It could also be one of the few drugs of its kind to be available orally. The current round of trials shows that the drug will need to be injected less frequently than competitors. The company trades with a market cap of $9 billion (in contrast to Lilly’s $720 billion market cap) and is still small enough that it could be bought before the expensive process of taking a drug to market. (Although the company recently raised a secondary offering that would advance marketing plans.) I would buy this up to $100 a share and expect it to continue to zoom as more good news, I expect, on the oral version gets released this quarter. I am adding the stock to my online portfolios today, Thursday, February 29. You can find a write up on this pick on my subscription JubakAM.com and free JubakPicks.com sites.
Yesterday, February 28, development-stage biotech Viking Therapeutics (VKTX) announced results from a Phase 2 training of its GLP-1 weight-loss drug candidate that that showed the potential for the VK2735 compound two move to be best in class in the $36.5 billion (revenue) market for GLP diabetes-control and weight-loss drugs. I will add Viking Therapeutic to my Volatility Portfolio and to my Jubak’s Picks Portfolio today, February 29, with a target price of $150.
